ClinicalTrials.gg
Active, not recruitingNCT05632939Updated Sep 10, 2025

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

A Phase 1/2 interventional study of ASKB589 +CAPOX+Sintilimab/Tislelizumab in Gastric Cancer and Gastroesophageal Cancer (GC), sponsored by AskGene Pharma, Inc.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by AskGene Pharma, Inc. (part of Beijing Aosaikang Pharmaceutical Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing sintilimab in Stomach Neoplasms — 29 open to participants now, 35 under way, 2 of them phase 3. sintilimab · Stomach Neoplasms.

Enrollment
10th of 44
62 · median 40
Started
2023
with 8 others
Phase 1/2
3 of 44
2 open now
Primary completion
2025-10
later than 12 of 34 live
Registered
16th of 44
by date
Lead sponsor
1 of 44
AskGene Pharma, Inc.

Among the 44 studies testing sintilimab in Stomach Neoplasms, this one is the 10th largest by enrollment, is one of 9 that started in 2023, is one of 3 in phase 1/2, reaches primary completion later than 12 of the 34 other live ones, and was the 16th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

29 of the 44 studies testing sintilimab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing sintilimab in Stomach Neoplasms, or all of them as a file.
02

Study summary

This was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in combination with CAPOX and PD-1 inhibitors in first-line treatment of patients with locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.

Read the detailed description

A two-part, dose-escalation and expansion study of ASKB589 was initiated to determine the MTD, PK, PD, and efficacy in combination with chemotherapy and PD-1 inhibitors.

03

Conditions studied

  • Gastric Cancer
  • Gastroesophageal Cancer (GC)

Browse trials for

Keywords

  • CLDN18.2
  • gastric cancer
  • gastroesophageal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histopathologically confirmed unresectable locally advanced, recurrent, or adenocarcinoma of the gastric and gastroesophageal junction currently ineligible for surgery and radical radiotherapy.
  2. Investigators determined that the present situation of the patient justifies chemotherapy plus immunotherapy as treatment.
  3. Tumor tissue samples are CLDN18.2 positive detected by central laboratory
  4. performance status 0-1.
  5. The results of the laboratory tests must meet all criteria
  6. of at least 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Known active central nervous system or suspected cancerous meningitis;
  2. There are moderate to large amounts of abdominal and pleural fluid.
  3. The presence of clinically uncontrollable third interspace fluid;
  4. Patients with any other malignant tumors within the past 5 years.
  5. Applicable to anti- drug therapy;
  6. Anti-CLDN18.2 antibody, antibody, or drug therapy at any time in the past;
  7. Patients have received antitumor therapy during the first 4 weeks before study drug use;
  8. Pregnant or lactating women; or women of childbearing age who have a positive blood pregnancy test during screening period; or women of childbearing age and their spouses who are unwilling to take effective measures during the period of this clinical trial and within 6 months after the end of the clinical trial;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    ASKB589 +CAPOX+Sintilimab/Tislelizumab

    Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab/Tislelizumab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years. ASKB589 is administered intravenously at a fixed dose. the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years.

    Drug: ASKB589 +CAPOX+Sintilimab/Tislelizumab

Interventions

  • DrugASKB589 +CAPOX+Sintilimab/Tislelizumab

    Drug pages: Omectatug · Sintilimab · Tislelizumab

    Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab/Tislelizumab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years. ASKB589 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events as assessed by CTCAE v5.0

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be presented.

    Time frame: up to 21 days following last dose

  2. The incidence and case number of DLT (Dose Limiting Toxicity) during observation period.

    DLT is short for Dose Limiting Toxicity,dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.

    Time frame: up to 21 days following last dose

  3. Maximum Tolerated Dose (MTD)

    The MTD was defined as the highest dose of ASKB589 not causing DLT in more than 33% of patients in the first treatment cycle.

    Time frame: up to 21 days following last dose

  4. The recommended dose

    The recommended dose will be determined during the dose escalation and dose expansion stage of the study.

    Time frame: from date of treatment start until data cut-off, up to 2 years

Secondary outcomes

  1. Pharmacokinetics:maximum Plasma Concentration [Cmax]

    Serum samples will be collected for Cmax analysis.

    Time frame: Up to 21 days after injection

  2. Pharmacokinetics:time to maximum observed plasma concentration (Tmax)

    Serum samples will be collected for Tmax analysis.

    Time frame: Up to 21 days after injection

  3. Pharmacokinetics:elimination rate constant(Kel)

    Serum samples will be collected for Kel analysis

    Time frame: Up to 21 days after injection

  4. Pharmacokinetics:terminal elimination half life (T1/2)

    Serum samples will be collected for T1/2 analysis.

    Time frame: Up to 21 days after injection

  5. Pharmacokinetics:apparent volume of distribution (Vz/F)

    Serum samples will be collected for Vz/F analysis.

    Time frame: Up to 21 days after injection

  6. Pharmacokinetics:Area Under Curve (AUC)

    Serum samples will be collected for AUC analysis.

    Time frame: Up to 21 days after injection

  7. Pharmacokinetics: Mean ResidenceTime(MRT)

    Serum samples will be collected for MRT analysis.

    Time frame: Up to 21 days after injection

  8. Pharmacokinetics: plasma clearance rate (CL)

    Serum samples will be collected for CL analysis.

    Time frame: Up to 21 days after injection

  9. Pharmacokinetics: steady-state peak concentration (Css_max)

    Serum samples will be collected for Css\_max analysis.

    Time frame: Up to 21 days after injection

  10. Pharmacokinetics: time to steady-state peak concentration (Tss_max)

    Serum samples will be collected for Tss\_max analysis.

    Time frame: Up to 21 days after injection

  11. Pharmacokinetics: minimum value of steady plasma drug concentration(Css_min)

    Serum samples will be collected for Css max analysis.

    Time frame: Up to 21 days after injection

  12. Evaluation of immunogenicity

    Incidence of anti-drug antibodies (ADA)

    Time frame: from date of treatment start until data cut-off, up to 2 years

  13. Objective response rate(ORR)

    Evaluation of objective response rate assessed by RECIST 1.1

    Time frame: from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years

  14. disease control rate(DCR)

    Evaluation of Disease control rate assessed by RECIST 1.1

    Time frame: from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years

  15. Duration of Response(DOR)

    Duration of response assessed by RECIST 1.1

    Time frame: from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years

  16. Progression free survival(PFS)

    Progression of tumor will be measured by RECIST v1.1

    Time frame: from date of treatment start until the date of disease progression or until death due to any causes, up to 2 years

  17. Overall survival(OS)

    defined as the time from the date of treatment start until date of death due to any cause.

    Time frame: from the date of treatment start until the documented date of death from any cause,up to 2 years.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Oct 2025, 32 months after the start.

Of 89 industry-sponsored phase 1/2 interventional studies under Stomach Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 109. This study's planned 32 months is below that.

Counting every sponsor, half of 156 studies reached it within 60 months; a quarter within 41 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Dec 1, 2022
StartActual
Feb 21, 2023
Primary completionEst.
Oct 31, 2025
CompletionEst.
Feb 10, 2026
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05632939
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Feb 21, 2023
Primary completion
Oct 31, 2025 (estimated)
Completion
Feb 10, 2026 (estimated)
Last update
Sep 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Omectatug · Sintilimab · Tislelizumab

Start the discussion